• 1
    Bartsch P, Saltin B. General introduction to altitude adaptation and mountain sickness. Scand J Med Sci Sports 2008; 18(Suppl 1):110.
  • 2
    Maggiorini M, Buhler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ 1990; 301:853855.
  • 3
    Mairer K, Wille M, Bucher T, Burtscher M. Prevalence of acute mountain sickness in the Eastern Alps. High Alt Med Biol 2009; 10:239245.
  • 4
    Jaksch A, Rohrer P, Hofmann P, Domej W. Limitation of exercise performance due to cigarette smoking and normobaric hypoxia. In: Domej W, Sumann G, Schobersberger B, Schobersberger W, eds. Jahrbuch 2011 Österreichische Gesellschaft für Alpin- und Höhenmedizin. Imst: Die Druckerei Egger, 2011:137153.
  • 5
    Steinacker JM, Tobias P, Menold E, et al. Lung diffusing capacity and exercise in subjects with previous high altitude pulmonary oedema. Eur Respir J 1998; 11:643650.
  • 6
    Bartsch P, Mairbaurl H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol 2005; 98:11011110.
  • 7
    Dehnert C, Grunig E, Mereles D, et al. Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude. Eur Respir J 2005; 25:545551.
  • 8
    Grunig E, Mereles D, Hildebrandt W, et al. Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol 2000; 35:980987.
  • 9
    Prabhakar NR, Peng YJ, Overholt JL, Kumar GK. Detection of oxygen sensing during intermittent hypoxia. Methods Enzymol 2004; 381:107120.
  • 10
    Scherrer U, Vollenweider L, Delabays A, et al. Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 1996; 334:624629.
  • 11
    Busch T, Bartsch P, Pappert D, et al. Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am J Respir Crit Care Med 2001; 163:368373.
  • 12
    Duplain H, Sartori C, Lepori M, et al. Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med 2000; 162:221224.
  • 13
    Hackett P, Oelz O. The Lake Louise consensus on the definition and quantification of altitude illness. In: Sutton J, Coates G, Houston C, eds. Hypoxia and mountain medicine. Burlington: Queen City Printers, 1992:327330.
  • 14
    Maggiorini M, Muller A, Hofstetter D, et al. Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med 1998; 69:11861192.
  • 15
    Dorrington KL, Clar C, Young JD, et al. Time course of the human pulmonary vascular response to 8 hours of isocapnic hypoxia. Am J Physiol 1997; 273(3 Pt 2):H1126H1134.
  • 16
    Song MY, Zwemer CF, Whitesall SE, D'Alecy LG. Acute and conditioned hypoxic tolerance augmented by endothelial nitric oxide synthase inhibition in mice. J Appl Physiol 2007; 102:610615.
  • 17
    Malyshev IY, Zenina TA, Golubeva LY, et al. NO-dependent mechanisms of adaptation to hypoxia. Nitric Oxide 1999; 3:105113.
  • 18
    Giulivi C, Kato K, Cooper CE. Nitric oxide regulation of mitochondrial oxygen consumption I: cellular physiology. Am J Physiol Cell Physiol 2006; 291:C1225C1231.
  • 19
    Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006; 176(Pt 1):213254.
  • 20
    Kato K, Giulivi C. Critical overview of mitochondrial nitric-oxide synthase. Front Biosci 2006; 11:27252738.
  • 21
    Brown GC. Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim Biophys Acta 2001; 1504:4657.
  • 22
    Palacios-Callender M, Hollis V, Frakich N, et al. Cytochrome c oxidase maintains mitochondrial respiration during partial inhibition by nitric oxide. J Cell Sci 2007; 120(Pt 1):160165.
  • 23
    Victor VM, Nunez C, D'Ocon P, et al. Regulation of oxygen distribution in tissues by endothelial nitric oxide. Circ Res 2009; 104:11781183.
  • 24
    Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282:879887.
  • 25
    Haberka M, Mizia-Stec K, Gasior Z, et al. Serum ADMA concentration—an independent factor determining FMD impairment in cardiac syndrome X. Ups J Med Sci 2009; 114:221227.
  • 26
    Lajer M, Tarnow L, Jorsal A, et al. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008; 31:747752.